Enliven Therapeutics, Inc. (NASDAQ:ELVN) CFO Sells $24,420.00 in Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN) CFO Benjamin Hohl sold 814 shares of the business’s stock in a transaction on Friday, October 18th. The stock was sold at an average price of $30.00, for a total transaction of $24,420.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Benjamin Hohl also recently made the following trade(s):

• On Friday, October 4th, Benjamin Hohl sold 10,218 shares of Enliven Therapeutics stock. The shares were sold at an average price of $27.51, for a total transaction of $281,097.18.
• On Monday, October 7th, Benjamin Hohl sold 1,270 shares of Enliven Therapeutics stock. The stock was sold at an average price of $27.51, for a total transaction of $34,937.70.
• On Friday, September 27th, Benjamin Hohl sold 4,250 shares of Enliven Therapeutics stock. The stock was sold at an average price of $24.27, for a total value of $103,147.50.
• On Monday, September 30th, Benjamin Hohl sold 2,000 shares of Enliven Therapeutics stock. The shares were sold at an average price of $25.33, for a total value of $50,660.00.
• On Tuesday, August 27th, Benjamin Hohl sold 4,250 shares of Enliven Therapeutics stock. The stock was sold at an average price of $22.54, for a total value of $95,795.00.
• On Wednesday, July 31st, Benjamin Hohl sold 991 shares of Enliven Therapeutics stock. The shares were sold at an average price of $27.53, for a total value of $27,282.23.
• On Monday, July 29th, Benjamin Hohl sold 5,250 shares of Enliven Therapeutics stock. The shares were sold at an average price of $26.68, for a total transaction of $140,070.00.

Enliven Therapeutics Stock Down 0.0 %

Shares of NASDAQ:ELVN opened at $28.97 on Thursday. Enliven Therapeutics, Inc. has a 52-week low of $9.80 and a 52-week high of $30.03. The business has a fifty day moving average of $24.52 and a two-hundred day moving average of $22.88. The stock has a market cap of $1.36 billion, a P/E ratio of -15.01 and a beta of 1.10.

Enliven Therapeutics (NASDAQ:ELVN) last released its quarterly earnings data on Tuesday, August 13th. The company reported ($0.41) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.58) by $0.17. On average, equities analysts anticipate that Enliven Therapeutics, Inc. will post -1.98 earnings per share for the current year.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reaffirmed a “buy” rating and set a $37.00 price objective on shares of Enliven Therapeutics in a research note on Tuesday, October 1st.

Institutional Trading of Enliven Therapeutics

Several institutional investors have recently made changes to their positions in ELVN. Quest Partners LLC grew its position in Enliven Therapeutics by 87.3% in the second quarter. Quest Partners LLC now owns 1,592 shares of the company’s stock worth $37,000 after acquiring an additional 742 shares during the period. EntryPoint Capital LLC acquired a new position in shares of Enliven Therapeutics in the 1st quarter valued at $167,000. SG Americas Securities LLC purchased a new position in shares of Enliven Therapeutics during the 3rd quarter worth $256,000. The Manufacturers Life Insurance Company acquired a new stake in shares of Enliven Therapeutics during the 2nd quarter worth about $322,000. Finally, Blackstone Inc. acquired a new stake in shares of Enliven Therapeutics during the 1st quarter worth about $443,000. Hedge funds and other institutional investors own 95.08% of the company’s stock.

About Enliven Therapeutics

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.